Medical IT and Diagnostic Product Company Decision Diagnostics Announces Patent Enforcement Strategy for Their Smart Phone Based EMR Technology
Jan 11, 2012, 09:15 ET
LOS ANGELES, Jan. 11, 2012 /PRNewswire/ -- Decision Diagnostics Corp., formerly known as InstaCare Corp., (OTCQB:ISCR), a leading developer of revolutionary Smart phone centric e-health care products and remote medical software applications, a leading provider of home medical supplies and point of care testing products for the chronically ill, a leading fulfillment provider of direct to patient diabetes programs, and the exclusive worldwide distributor of the Shasta Genstrip, today announced its Patent Enforcement Strategy for the upcoming and expected patent covering its revolutionary Smartphone EMR technologies [email protected] and [email protected]
The Company's patent, filed in February 2010, has 104 separate patent claims for unique proprietary technology developed for and the foundation of its [email protected] and [email protected] mobile smart phone based EMR products. The company's patent application was published for comments in late September 2011, and based on discussions and a review of other parallel but unrelated patents granted in the medical field, the Company anticipates patent approval in the next several months..
Keith Berman, CFO and Secretary of Decision Diagnostics Corp. commented, "Patent enforcement has become a useful tool for the protection of proprietary technology. Oftentimes companies spend millions of dollars developing technologies only to see these developments become part of other products without the permission of the original developer."
In December 2011 the company created a patent prosecution pool valued at approximately $1.25 million. Subsequently the company engaged Michael Belcher, Esq. of the firm Hunter Molloy & Salcido to manage the patent prosecution pool and to hire expert firms on an as-needed basis to prosecute patent infringement claims in the U.S. and Canada. It is the Board's opinion that the Company should also benefit from the June 2010 Supreme Court ruling on Bilski v. Kappos.
Mr. Berman concluded, "With all of the interest in mobile medical software products, the evolution and power of smart phones and the immediacy of medical data required by physicians, our [email protected] and [email protected] products require a strong, strategic patent enforcement plan. We believe our strategy will add great value to our technologies and create potential royalty streams."
For more information about Decision Diagnostics Corp. and its revolutionary [email protected] cell phone centric technologies, and, Pharma Tech Solutions, Inc. and its Shasta Genstrip, please visit the Decision Diagnostics web site www.decisiondiagnostics.com or the Pharma Tech web site www.pharmatechdirect.com, or call the company at (805) 446-2973.
This news release contains forward-looking statements about our business, or financial condition and prospects that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this news release, words such as "believes," "expects," "intends," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain forward-looking statements not accompanied by such expressions.
SOURCE Decision Diagnostics Corp.
Share this article